Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
(4) - EconoTimes)
BERKELEY, Calif., March 01, 2018 -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that on March 1, 2018 the Compensation Committee of Dynavax’s Board of Directors approved the grant of inducement stock options to purchase an aggregate of 30,000 shares of common stock to six new employees. These awards were granted pursuant to the Dynavax Technologies Corporation Inducement Plan, as an inducement material to the new employees entering into employment with Dynavax, in accordance with the NASDAQ Listing Rule 5635(c)(4).
Dynavax granted stock options to purchase shares of Dynavax’s common stock to the new employees with an exercise price of $16.05 per share, the closing price of Dynavax’s common stock on March 1, 2018, the effective date of such grants. The stock options awarded vest over a three-year period, with one-third of the shares subject to such awards vesting on the first anniversary of the award’s vesting commencement date, and 1/36th of the shares subject to such awards vesting monthly thereafter, subject to each such employee’s continued employment with Dynavax on such vesting dates.
Dynavax is providing this information in accordance with NASDAQ Listing Rule 5635(c)(4).
About Dynavax
Dynavax is a fully-integrated biopharmaceutical company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Dynavax discovers and develops novel vaccines and immuno-oncology therapeutics. The Company’s first commercial product, HEPLISAV-B™ [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the United States. Dynavax's lead immunotherapy product, SD-101, is an investigational cancer immunotherapeutic currently being evaluated in Phase 1/2 studies and its second cancer immunotherapeutic, DV281, is in Phase 1 development. For more information, visit www.dynavax.com.
Contact:
David Burke
Director, IR & Corporate Communications
510.665.7269
[email protected]
